| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bicarbonate one central carbon atom surrounded by three oxygen atoms in a triogonal planer arrangement with a hydrogen atom attached to one of the oxygens. -Bicarbonate’s primary role is in pH buffering. Its administration has been studied as an adjuvant strategy to modify the tumor microenvironment. -Many solid tumors exhibit an acidic microenvironment due to high rates of glycolysis (the “Warburg effect”) and poor perfusion. Bicarbonate supplementation can buffer this acidity, raising the extracellular pH. -By modulating pH, bicarbonate may influence pathways tied to glycolysis and oxidative phosphorylation Bicarbonate — usually discussed clinically as sodium bicarbonate (NaHCO3; standard abbreviation HCO3−/NaHCO3) — is an endogenous extracellular buffer and alkalinizing agent rather than a conventional cytotoxic anticancer drug. It is formally classified as a small-molecule inorganic salt / systemic buffer therapy. In cancer research, its relevance comes from partial neutralization of acidic tumor extracellular pH, with downstream effects on invasion, immune suppression, and pH-dependent drug distribution. The best-supported oncology use-case is tumor-microenvironment buffering as an adjunct strategy; localized bicarbonate delivery has also been studied in hepatocellular carcinoma embolization settings. Major practical constraints are sodium load, gastrointestinal intolerance with oral dosing, and the fact that systemic homeostasis tightly limits how far tumor pH can be shifted. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral bicarbonate is readily absorbed, distributes mainly in extracellular fluid, and is rapidly integrated into normal acid-base physiology; IV administration is fully bioavailable. PK is less about classic tissue targeting and more about transient systemic buffering capacity. Delivery is constrained by gastric neutralization, GI intolerance, renal handling, CO2 generation, and sodium burden. In-vitro vs systemic exposure relevance: Bicarbonate is not primarily a direct high-concentration cytotoxin under standard systemic use. The main translational effect is extracellular pH modulation, not sustained intracellular drug-like exposure. In-vitro alkalinization experiments can overstate direct cancer-cell killing relative to what is usually achievable safely with oral systemic dosing. Clinical evidence status: Strong preclinical evidence; limited human evidence. Human oncology data are mainly small pilot/adjunct studies, including localized bicarbonate use with TACE and small supportive-care / feasibility studies of oral bicarbonate. There is no established broad anticancer monotherapy role. The extracellular pH of malignant solid tumors is acidic, in the range of 6.5 to 6.9, whereas the pHe of normal tissues is significantly more alkaline, 7.2 to 7.5Acidic pHe may induce release of cathepsin proteinase activity in vitro, which is generally believed to be involved in local invasion and tissue remodeling Cancer Mechanism Matrix
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 5613- | NaHCO3, | The Potential Role of Systemic Buffers in Reducing Intratumoral Extracellular pH and Acid-Mediated Invasion |
| - | Study, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:43 Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid